COVID-19感染对州创伤系统损伤后结局的影响
该回顾性队列研究纳入2020年3月21日至7月31日宾夕法尼亚州创伤中心收治的15,550例患者,其中8,170例(52.5%)接受COVID-19检测,219例(2.7%)阳性。采用粗化精确匹配的多变量回归分析,COVID-19阳性患者较阴性患者住院死亡风险显著升高(OR 6.05,95%CI 2.29-15.99),任何并发症风险升高(OR 1.85,95%CI 1.08-3.16),肺部并发症风险显著升高(OR 5.79,95%CI 2.02-16.54)。未调整死亡率阳性组为9.1%,阴性组为4.7%(p<0.0001),中位住院时间分别为5天和4天(p<0.001)。
要点
- 创伤合并COVID-19感染患者住院死亡风险显著升高(OR 6.05,95%CI 2.29-15.99),应纳入预后告知和资源分配考量。
- COVID-19阳性创伤患者任何并发症风险升高(OR 1.85,95%CI 1.08-3.16),肺部并发症风险尤为显著(OR 5.79,95%CI 2.02-16.54)。
- 未调整死亡率COVID-19阳性组为9.1%,阴性组为4.7%(p<0.0001);中位住院时间阳性组5天,阴性组4天(p<0.001)。
- COVID-19阳性组火器伤占比11.9%,阴性组5.1%(p<0.001);阳性组无保险比例10.1%,阴性组5.6%(p=0.002)。
- 两组年龄和性别相似,损伤严重程度相似,但阳性组白人比例较低(53.5% vs 74.7%,p<0.0001)。
适用人群与场景
- 2020年3月21日至7月31日期间入住宾夕法尼亚州创伤中心的创伤患者,共15,550例纳入分析,其中8,170例(52.5%)接受COVID-19检测。
- 暴露组为COVID-19阳性(COV+)患者219例(2.7%),对照组为COVID-19阴性(COV-)患者,另包括未检测患者用于人口学和损伤特征比较。
诊断标准与关键阈值
- COVID-19阳性定义:研究期间接受检测且结果阳性(COV+)。
- 主要结局:住院死亡;次要结局:住院时间(length of stay)和并发症。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 创伤合并COVID-19感染患者住院死亡风险显著升高(OR 6.05,95%CI 2.29-15.99),需警惕病情恶化。
- COVID-19阳性创伤患者肺部并发症风险显著升高(OR 5.79,95%CI 2.02-16.54),应加强肺部并发症监测。
- COVID-19阳性组火器伤占比更高(11.9% vs 5.1%,p<0.001),提示该人群损伤机制可能更严重。
研究设计与关键结果
- 研究类型:回顾性队列研究,纳入宾夕法尼亚州创伤中心2020年3月21日至7月31日收治的15,550例患者,其中8,170例(52.5%)接受COVID-19检测,219例(2.7%)阳性。
- 主要终点:采用粗化精确匹配的多变量回归,COVID-19阳性患者住院死亡风险显著高于阴性患者(OR 6.05,95%CI 2.29-15.99)。
- 关键次要终点:任何并发症OR 1.85(95%CI 1.08-3.16),肺部并发症OR 5.79(95%CI 2.02-16.54);未调整死亡率9.1% vs 4.7%(p<0.0001),中位住院时间5天 vs 4天(p<0.001)。
- 人口学与损伤特征:两组年龄和性别相似,损伤严重程度相似;COVID-19阳性组白人比例较低(53.5% vs 74.7%,p<0.0001),无保险比例较高(10.1% vs 5.6%,p=0.002),火器伤比例较高(11.9% vs 5.1%,p<0.001)。
证据类型、等级与局限
- 证据类型:回顾性队列研究(Prognostic Study),证据等级Level II。
- 局限:回顾性设计,单州创伤系统数据,仅52.5%患者接受COVID-19检测,阳性样本量较小(219例),可能存在检测偏倚和未测量混杂。
对床旁实践的改变
- 创伤合并COVID-19感染患者预后较差,应在患者及家属沟通中纳入死亡和并发症风险升高的信息。
- 提示在COVID-19大流行期间创伤中心应据此进行资源分配,加强对阳性患者的监护和并发症防治。
- 适用人群:创伤中心收治的创伤患者;不适用人群:原文未提及。
- 常见陷阱:不能将本研究的OR值直接作为其他人群或时期的决策阈值;检测率仅52.5%,未检测患者可能低估COVID-19负担。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The COVID-19 pandemic reshaped the health care system in 2020. COVID-19 infection has been associated with poor outcomes after orthopedic surgery and elective, general surgery, but the impact of COVID-19 on outcomes after trauma is unknown.
METHODS: We conducted a retrospective cohort study of patients admitted to Pennsylvania trauma centers from March 21 to July 31, 2020. The exposure of interest was COVID-19 (COV+) and the primary outcome was inpatient mortality. Secondary outcomes were length of stay and complications. We compared demographic and injury characteristics between positive, negative, and not-tested patients. We used multivariable regression with coarsened exact matching to estimate the impact of COV+ on outcomes.
RESULTS: Of 15,550 included patients, 8,170 (52.5%) were tested for COVID-19 and 219 (2.7%) were positive (COV+). Compared with COVID-19-negative (COV-) patients, COV+ patients were similar in terms of age and sex, but were less often white (53.5% vs. 74.7%, p < 0.0001), and more often uninsured (10.1 vs. 5.6%, p = 0.002). Injury severity was similar, but firearm injuries accounted for 11.9% of COV+ patients versus 5.1% of COV- patients (p < 0.001). Unadjusted mortality for COV+ was double that of COV- patients (9.1% vs. 4.7%, p < 0.0001) and length of stay was longer (median, 5 vs. 4 days; p < 0.001). Using coarsened exact matching, COV+ patients had an increased risk of death (odds ratio [OR], 6.05; 95% confidence interval [CI], 2.29-15.99), any complication (OR, 1.85; 95% CI, 1.08-3.16), and pulmonary complications (OR, 5.79; 95% CI, 2.02-16.54) compared with COV- patients.
CONCLUSION: Patients with concomitant traumatic injury and COVID-19 infection have elevated risks of morbidity and mortality. Trauma centers must incorporate an understanding of these risks into patient and family counseling and resource allocation during this pandemic.
LEVEL OF EVIDENCE: Level II, Prognostic Study.
参考来源
- Kaufman EJ, Ong AW, Cipolle MD, et al. The impact of COVID-19 infection on outcomes after injury in a state trauma system. J Trauma Acute Care Surg. 2021. PMID: 34074996. doi:10.1097/TA.0000000000003310
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。